%0 Journal Article
%T RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets
%A Aiste Degesys
%A Arnold L. Oronsky
%A Bryan T. Oronsky
%A Christina Brzezniak
%A Corey A. Carter
%A Harry Lybeck
%A Jan J. Scicinski
%A Joseph Roswarski
%A Michelle M. Kim
%A Neil Oronsky
%A Pedro Cabrales
%A Scott Z. Caroen
%A Tony Reid
%J Archive of "Case Reports in Oncology".
%D 2016
%R 10.1159/000444631
%X RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT ({"type":"clinical-trial","attrs":{"text":"NCT02489903","term_id":"NCT02489903"}}NCT02489903), which reexposes patients to previously effective but refractory platinum doublets after treatment with RRx-001. The purpose of this case study is first to report a partial response to carboplatin and etoposide in a patient with small-cell lung cancer pretreated with RRx-001, indicating episensitization or resensitization by epigenetic mechanisms, and second to discuss the literature related to small-cell lung cancer and episensitization
%K Small-cell lung cancer
%K Resistance
%K Platinum doublets
%K Epigenetic
%K Resensitization
%K Episensitization
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821137/